Immuno-Oncology Panel

Immuno-Oncology Research

Immunogenomics is a field of study that combines immunology and genomics to gain insights into the immune system's response to diseases, particularly cancer, by analyzing the expression profile of immune-related genes and studying genetic mutations and neoantigens in tumors.

To characterize the phenotype of tumor-microenvironment interactions, various sequencing approaches are employed. CD Genomics Immuno-Oncology Panel offers a valuable tool for studying immune-related gene expression in cancer, it is always recommended to complement such targeted approaches with additional sequencing techniques, such as whole-genome or whole-transcriptome sequencing, to capture a more comprehensive view of the genetic and functional landscape of the immune response in cancer.

Immune Repertoire Analysis Panel (targeting genes related to immunoglobulin, BCR and TCR) is also available in CD Genomics.

Key Features and Benefits

• Allows for simultaneous analysis of up to 1300 genes
• Uses only 1 µL of biological sample (1-100 ng RNA) focused on tumor/immune interaction
• Exceptional data quality through our in-house sequencing platforms
• Precise quantification with unparalleled sensitivity, specificity, and precision
• Focus on tumor, microenvironment, and immune response
• All assays are subject to CD Genomics' strict technical validation and quality control procedures

Specifications of Immuno-Oncology Panel

Specifications of Immuno-Oncology Panel Pro

Panel Contents

How Does it Work

Our Immuno-Oncology Panel works by leveraging next-generation sequencing (NGS) technology to analyze gene expression related to immuno-oncology.

Applications

• TCGA Tumor-Subtyping: The panel can be used for tumor-subtyping analysis based on the gene expression patterns. By identifying specific gene signatures, researchers can classify tumors into different subtypes, providing insights into tumor heterogeneity and potential therapeutic strategies.
• Immuno-phenotyping TILs: Tumor-infiltrating lymphocytes (TILs) play a crucial role in the immune response against cancer. The panel can be utilized to profile the immune cell populations present within the tumor microenvironment, enabling the characterization and quantification of TILs.
• Immuno-resistance Pathways: The panel allows for the investigation of immune resistance pathways in cancer. By analyzing gene expression patterns associated with immune-resistance, researchers can identify key molecular mechanisms that contribute to immune evasion and develop strategies to overcome resistance.
• Tumor Inflammation: The panel can provide insights into tumor inflammation by analyzing gene expression related to pro-inflammatory and anti-inflammatory pathways. This information can help researchers understand the inflammatory microenvironment of tumors and its impact on tumor progression and response to therapy.
• Cytokine Profiling: Cytokines are important signaling molecules involved in immune responses. The panel can be used to profile cytokine expression, providing a comprehensive assessment of the cytokine landscape within the tumor microenvironment and its potential implications for immune modulation.
• Immuno-suppression Phenotyping: The panel can aid in the phenotyping of immunosuppressive mechanisms within the tumor microenvironment. By analyzing gene expression associated with immune checkpoints and regulatory T cells, researchers can identify immunosuppressive pathways and develop strategies to modulate them.
• DNA Repair Mechanisms: The panel can provide insights into DNA repair mechanisms in cancer. By analyzing gene expression associated with DNA repair pathways, researchers can evaluate the DNA repair capacity of tumors and potentially identify vulnerabilities that can be targeted with therapies.
• Drug Target Assessment: The panel can assist in the assessment of drug targets in the context of immuno-oncology. By analyzing gene expression related to specific drug targets, researchers can evaluate the potential efficacy of targeted therapies and guide treatment decision-making.